Urinary System Tumor

Posted On 2018-04-11 07:54:54
Urinary System Tumor
Editors: Dingwei Ye, Philippe E. Spiess, Simon Horenblas

Publisher: AME Publishing Company; 1st edition (2017)
ISBN-13: 978-9887784135
Hardcover: 531 pages
Language: English
Available at:
As the study of molecular biology continues to develop, we find ourselves increasingly recognizing the biological characteristics and pathogenesis of urinary system tumors, and diagnosis and treatment concepts, methods, and techniques have seen great improvements over the years. Many scholars have come together to compile this book in order to introduce the latest development of urinary system tumors in a comprehensive and systematic manner.


Dingwei Ye Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Philippe E. Spiess Department of Genitourinary Oncology, Moffitt Cancer Center, Tampa, FL, USA
Simon Horenblas Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands

Associate Editors

Yao Zhu Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China
Siamak Daneshmand Institute of Urology, USC/Norris Comprehensive Cancer Center, Los Angeles, CA, USA
Badrinath R. Konety Department of Urology, University of Minnesota, Minneapolis, MN, USA
Maarten Albersen Department of Urology, University Hospitals Leuven, Leuven, Belgium
Table of Contents
Biology of Urinary System Tumor
1 Androgen receptor gene mutation, rearrangement, polymorphism
12 Androgen receptor epigenetics
22 Androgen receptor genomic regulation
42 Decoding the androgen receptor splice variants
51 Androgen receptor-mediated non-genomic regulation of prostate cancer cell proliferation
61 Novel non-AR therapeutic targets in castrate resistant prostate cancer
74 Steroid hormone synthetic pathways in prostate cancer
90 Translating insights of AR signaling from mouse models
95 Epithelial mesenchymal transition (EMT) in prostate growth and tumor progression
105 The role of microRNAs in prostate cancer progression
119 Cancer stem cells in prostate cancer
131 Bacille-Calmette-Guerin non-responders: how to manage
141 TGF-β mediated DNA methylation in prostate cancer
152 Somatostatin receptors over-expression in castration resistant prostate cancer detected by PET/CT: preliminary report of in six patients
Diagnostic Methods of Urinary System Tumor
158 Prostate cancer magnetic resonance imaging (MRI): multidisciplinary standpoint
171 The current and future role of magnetic resonance imaging in prostate cancer detection and management
187 Utility of ADC measurement on diffusion-weighted MRI in differentiation of prostate cancer, normal prostate and prostatitis
194 Near-infrared uorescence and nuclear imaging and targeting of prostate cancer
Treatment of Urinary System Tumor
Surgical Treatment of Urinary System Tumor
205 Standard cystectomy ts all: truth or myth?
212 Outlining the limits of partial nephrectomy
219 Penile rehabilitation after radical prostatectomy: does it work?
233 Cytoreductive surgery in the era of targeted molecular therapy
242 Presentation, management, and outcomes of complications following prostate cancer therapy
Chemotherapy of Urinary System Tumor
248 Risk based neoadjuvant chemotherapy in muscle invasive bladder cancer
258 Beyond chemotherapy for advanced disease—the role of EGFR and PD-1 inhibitors
Radiotherapy of Urinary System Tumor
265 Radiotherapy for prostate cancer and sexual health
272 Stereotactic body radiotherapy for organ-con ned prostate cancer
285 Proton beam radiation therapy of prostate cancer - history, results, and future directions
296 Impact of comorbidity in elderly prostate cancer patients treated with brachytherapy
Multidisciplinary Comprehensive Treatment of Urinary System Tumor
303 Current clinical challenges in prostate cancer
318 Sequence of treatment in locally advanced and metastatic renal cell carcinoma
334 Advances in the treatment of testicular cancer
344 Upper urinary tract disease: what we know today and unmet needs
356 Indications for biopsy and the current status of focal therapy for renal tumours
367 Active surveillance and focal therapy for low-intermediate risk prostate cancer
380 Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer
390 Mechanisms of resistance in castration-resistant prostate cancer (CRPC)
406 Surgery and hormonal treatment for prostate cancer and sexual function
413 Challenges to treat hypogonadism in prostate cancer patients: implications for endocrinologists, urologists and radiotherapists
422 Role of hormonal therapy for prostate cancer: perspective from Japanese experiences
435 How to evaluate sexual health in cancer patients: development of the EORTC sexual health questionnaire for cancer patients
443 Pharmacologic and surgical therapies for sexual dysfunction in male cancer survivors
455 Co-constructing sexual recovery after prostate cancer: a qualitative study with couples
463 Couples-based interventions following prostate cancer treatment: a narrative review
474 The argument for palliative care in prostate cancer
477 Prevention of bone metatasis in prostate cancer by denosumab: Unneeded endpoint or unmet need?
480 Contemporary and future insights into fertility preservation in male cancer patients
494 A second opportunity to come for anti-angiogenics in prostate cancer?
498 Treatment of localized prostate cancer in elderly patients
503 The primary health care physician and the cancer patient: tips and strategies for managing sexual health
517 Future perspectives of prostate cancer therapy

Click the book to view the entire PDF